Evolving Concepts and Challenges in Sepsis and MODS

...a brief history...from chaos to order...
  • A. Gullo
Conference paper


Sepsis is a life-threatening condition in patients admitted to critical care units. Sepsis consumes considerable healthcare resources in acute care hospitals. Considering the rapid evolution of knowledge,few studies on sepsis epidemiology are available [1, 2]; the sepsis-related mortality rate has persisted despite recent advances in understanding the complex pathophysiology of sepsis and significant improvements in the clinician’s ability to monitor and provide high technological function supports and management for critically ill patients in today’s intensive care unit (ICU) (Tables 1 and 2).


Septic Shock Severe Sepsis Organ Dysfunction Systemic Inflammatory Response Syndrome Immunomodulatory Therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Salvo I, De Cian W, Musicco M, et al (1995) The Sepsis Study Group; The Italian sepsis study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 21: 5244–5249CrossRefGoogle Scholar
  2. 2.
    Rangel Frausto MS, Pittet D, Costigan M, et al (1995) The natural history of the systemic inflammatory response syndrome ( SIRS ). JAMA 273: 117–123PubMedCrossRefGoogle Scholar
  3. 3.
    Opal SM, Fisher CJ Jr, Dhainaut JF, et al (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis. A phase III, randomised, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25: 1115–1124PubMedCrossRefGoogle Scholar
  4. 4.
    Bernard GR, Wheeler AP, Russell JA, et al (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336: 912–918PubMedCrossRefGoogle Scholar
  5. 5.
    Centers for Disease Control (1990) Increase in national hospital discharge survey rates for septicaemia—United States, 1979–1987. JAMA 263: 937–938CrossRefGoogle Scholar
  6. 6.
    Kieft H, Hoepelman AI, Zhou W, et al (1993) The sepsis syndrome in a Dutch university hospital. Clinical observations. Arch Intern Med 153: 2241–2247PubMedCrossRefGoogle Scholar
  7. 7.
    Bone RC, Balk RA, Cerra FB, et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644–1655PubMedCrossRefGoogle Scholar
  8. 8.
    Angus DC, Linde-Zwirble, Lidicker J, et al (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303–1310PubMedCrossRefGoogle Scholar
  9. 9.
    Sprung CL, Bernard GR, Dellinger RP (2001) Guidelines for the management of severe sepsis and septic shock. Intensive Care Med 27 [Suppl]: S1 - S134Google Scholar
  10. 10.
    Sprung CL, Bernard GR, Dellinger RP (2001) Guidelines for the management of severe sepsis and septic shock. Introduction. Intensive Care Med 27 [Suppl 1]: Sl-S2CrossRefGoogle Scholar
  11. 11.
    Stedman’s Medical Dictionary (1995) 36th edn Williams and Wilkins, BaltimoreGoogle Scholar
  12. 12.
    Pinsky MR, Vincent JL, Deviere J, et al (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103: 565–575PubMedCrossRefGoogle Scholar
  13. 13.
    American College of Chest Physicians/Society of Critical Care Medicine (1997) Consensus Conference defmitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 25: 1789–1795CrossRefGoogle Scholar
  14. 14.
    Knaus WA, Harrell FE, Wagner DP (1994) Defining sepsis. JAMA 271: 1876–1878CrossRefGoogle Scholar
  15. 15.
    Vincent JL (1997) Dear SIRS, I’m sorry to say that I don’t like you…Crit Care Med 25: 372–374Google Scholar
  16. 16.
    Problem of sepsis. European Society of Intensive Care Medicine (1994) Intensive Care Med 20: 300–304CrossRefGoogle Scholar
  17. 17.
    Dobb GJ (1991) Multiple organ failure-words mean what I say they mean. Intensive Care World 8: 157–160Google Scholar
  18. 18.
    Barriere SL, Lowry SF (1995) An overview of mortality risk prediction in sepsis. Crit Care Med 23: 376–393.PubMedCrossRefGoogle Scholar
  19. 19.
    Vincent JL, Moremùno R, Takala J, et al (1996) The SOFA ( Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 22: 707–710PubMedCrossRefGoogle Scholar
  20. 20.
    Vincent JL, De Mendonca A, Cantraine F, et al (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentric, prospective study. Crit Care Med 26: 1793–1800PubMedCrossRefGoogle Scholar
  21. 21.
    Baumgartner JD, Bula C, Vaney C, et al (1992) A novel score for predicting the mortality of septic shock patients. Crit Care Med 20: 953–960PubMedCrossRefGoogle Scholar
  22. 22.
    Hebert PC, Drummond AJ, Singer J, et al (1993) A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 19: 137–144Google Scholar
  23. 23.
    Bernard GR (1998) Quantification of organ dysfunction: seeking standardization. Crit Care Med 26: 1767–1768PubMedCrossRefGoogle Scholar
  24. 24.
    Knaus WA, Wagner DP, Draper EA, et al (1991) The APACHE III prognostic system. Risk prediction of hospital mortality in critically ill hospitalised adults. Chest 100: 1619–1636PubMedCrossRefGoogle Scholar
  25. 25.
    Le Gall JR, Loirat P, Alperovitch A, et al (1984) A simplified acute physiology score of ICU patients. Crit Care Med 12: 975–977PubMedCrossRefGoogle Scholar
  26. 26.
    Marshall JC, Cook DJ, Christou NV, et al (1995) Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23: 1638–1652PubMedCrossRefGoogle Scholar
  27. 27.
    Le Gall JR, Klar J, Lemeshow S, et al for the ICU scoring group (1996). The Logistic Organ Dysfunction System. A new way to assess organ dysfunction in the intensive care unit. JAMA 376: 802–810Google Scholar
  28. 28.
    Cressman DE, Greenbaum LE, DeAngelis RA, et al (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274: 1379–1383PubMedCrossRefGoogle Scholar
  29. 29.
    Deutschman CS (1998) Acute-phase responses and SIRS/MODS: the good, the bad, and the nebulous. Crit Care Med 26: 1630–1631PubMedCrossRefGoogle Scholar
  30. 30.
    Bone RC (1995) Sepsis and controlled trials: the odyssey continues. Crit Care Med 25: 1313–1315CrossRefGoogle Scholar
  31. 31.
    Dellinger RP (2001) Bad and good news in pathophysiology, prevention, and management of sepsis. In: Sepsis and organ dysfunction. Baue AE, Berlot G, Gullo A, Vincent JL (eds) Springer, Berlin Heidelberg New YorkGoogle Scholar
  32. 32.
    Bone RC (1996) Toward a theory regarding the pathogenesis of the inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24: 163–172PubMedCrossRefGoogle Scholar
  33. 33.
    Abraham E (1999) Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 25: 556–566PubMedCrossRefGoogle Scholar
  34. 34.
    Cohen J (1999) The “failure” of clinical trials in sepsis. Curr Opin Crit Care 339–340Google Scholar
  35. 35.
    Marshall JC (ed) (1999) Sepsis, vol. 3. KluwerGoogle Scholar
  36. 36.
    Keane MP, Strieter RM (2000) Chemokine signalling in inflammation. Crit Care Med 28 [Suppl]: N13 - N26PubMedCrossRefGoogle Scholar
  37. 37.
    Yaffe MB, Fink MP (2000) Cellular signalling in critical care. Putting the pieces together. Crit Care Med 28 [Suppl]: N1 - N2PubMedCrossRefGoogle Scholar
  38. 38.
    Hotchkiss RS, Swanson PE, Freeman BD, et al (1999) Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27: 1230–1251PubMedCrossRefGoogle Scholar
  39. 39.
    Abraham E, Matthay MA, Dinarello CA, et al (2000) Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med 28: 232–235PubMedCrossRefGoogle Scholar
  40. 40.
    Le-Barillec K, Henneke P, Golenbock DT (2000) Toll receptors: guardians of the immune system and effectors of septic shock. Advances in sepsis. ReMEDICA, pp 23–30Google Scholar
  41. 41.
    Beutler B, Poltorak A (2001) Sepsis and evolution of the innate immune response. Crit Care Med 29: S2 - S7PubMedCrossRefGoogle Scholar
  42. 42.
    Ulevitch RJ (2001) New therapeutic targets revealed through investigations of innate immunity. Crit Care Med 29: S8 - S12PubMedCrossRefGoogle Scholar
  43. 43.
    Carlet J (2001) Immunological therapy in sepsis: currently available. Intensive Care Med 27: 593 - S103CrossRefGoogle Scholar
  44. 44.
    Dhainaut JF, Giroir B, Opal S (2001) Introduction to the second Margaux Conference on Critical Illness. Sepsis: interface between inflammation, coagulation, and the endothelium. Crit Care Med 29: S1CrossRefGoogle Scholar
  45. 45.
    Fourrier F, Chopin C, Huart JJ, et al (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104: 882–888PubMedCrossRefGoogle Scholar
  46. 46.
    Baudo F, Caimi TM, Cataldo F de, et al (1998) Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or post-surgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 24: 336–342PubMedCrossRefGoogle Scholar
  47. 47.
    Eisele B, Lamy M, Thijs LG, et al (1998) Anti-thrombin III in patients with severe sepsis: a randomised, placebo-controlled, double blind. Multicenter trial plus a meta-analysis on all randomised placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24: 663–672PubMedCrossRefGoogle Scholar
  48. 48.
    Riess H (2000) Antithrombin in severe sepsis. “New” indication of an “old” drug. Intensive Care Med 26: 657–665PubMedCrossRefGoogle Scholar
  49. 49.
    Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709PubMedCrossRefGoogle Scholar
  50. 50.
    Baue AE (1999) Introduction in sepsis and organ dysfunction. In: Baue AE, Berlot G, Gullo A, Vincent JL (eds) Sepsis and organ dysfunction, Springer Verlag Italia, Milan 13–19Google Scholar
  51. 51.
    Baue AE (1998) The complexities of sepsis and organ dysfunction. In: Baue AE, Berlot G, Gullo A, Vincent JL (eds) Sepsis and organ dysfunction, Springer Verlag Italia, Milan 23–31Google Scholar
  52. 52.
    Baue AE (2001) Sepsis and organ dysfunction: an overview of the new science and new biology. In: Baue AE, Berlot G, Gullo A, Vincent Jl (eds) Sepsis and organ dysfunction, Springer Verlag Italia, Milan 123–132Google Scholar
  53. 53.
    Bion JF, Brun-Buisson C (2000) Introduction — infection and critical illness: genetic and environmental aspects of susceptibility and resistance. Intensive Care Med 26: S1 - S2PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2002

Authors and Affiliations

  • A. Gullo

There are no affiliations available

Personalised recommendations